Despite the fact that all patients have the same syndromic condition, it is observed that the patients of the study group (PD+IR+) show an altered expression of genes that participate, via very different pathways, in bone metabolism (IL1B, IL1RN, PTK2, BGLAP, FOXO1A). The gene discussed is PTK2; the disease is Parkinson disease.